featured
Efficacy and Safety of Roflumilast Foam 0.3% in Adolescents and Adults With Seborrheic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
J Am Acad Dermatol 2024 Jan 20;[EPub Ahead of Print], A Blauvelt, ZD Draelos, L Stein Gold, J Alonso-Llamazares, N Bhatia, J DuBois, SB Forman, M Gooderham, L Green, ST Guenthner, AA Hebert, E Lain, AY Moore, KA Papp, M Zirwas, S Kato, S Snyder, D Krupa, P Burnett, DR Berk, DH ChuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.